^
Association details:
| Biomarker: | PLK1 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET
Published date:
10/04/2022
Excerpt:
Combining the MAPK pathway inhibitor trametinib with the RET inhibitor pralsetinib (both of which are clinically approved for some lung cancers) induced tumor regression and prolonged survival in a mouse model of lung cancer with high PLK1 abundance.
DOI:
10.1126/scisignal.abj400
